Spanish drugmaker Grifols appoints new finance chief as shake-up continues
July 4 (Reuters) -Spanish drugmaker Grifols GRLS.MC has appointed Rahul Srinivasan as chief financial officer, the company said on Thursday, as the company reshuffles management after a short-seller fund questioned its accounting.
The accounting accusations in a report by Gotham City Research last January sparked a slump in the Grifols share price. Grifols has denied the accusations and also filed a lawsuit in the United States against the fund and its founder.
Srinivasan will start on Sept. 16, succeeding Alfredo Arroyo, who is retiring after 17 years at the company, Grifols said in Thursday's filing to the Spanish stock market regulator.
In February Grifols appointed Nacho Abia as chief executive in place of Thomas Glanzmann, who remained as chairman.
Reporting by Matteo Allievi
Editing by Inti Landauro and David Goodman
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
